Search

Your search keyword '"Woodward, David F."' showing total 294 results
Start Over Author "Woodward, David F."
294 results on '"Woodward, David F."'

2. Prostanoid receptors in GtoPdb v.2023.1

Author

Clapp, Lucie, primary, Giembycz, Mark, primary, Heinemann, Akos, primary, Jones, Robert L., primary, Narumiya, Shuh, primary, Norel, Xavier, primary, Sugimoto, Yukihiko, primary, Woodward, David F., primary, and Yao, Chengcan, primary

Published
2023
Full Text
View/download PDF

3. Functional rewiring of G protein-coupled receptor signaling in human labor

Author

Walker, Abigail R., primary, Larsen, Camilla B., additional, Kundu, Samit, additional, Stavrinidis, Christina, additional, Kim, Sung Hye, additional, Inoue, Asuka, additional, Woodward, David F., additional, Lee, Yun S., additional, Migale, Roberta, additional, MacIntyre, David A., additional, Terzidou, Vasso, additional, Fanelli, Francesca, additional, Khanjani, Shirin, additional, Bennett, Phillip R., additional, and Hanyaloglu, Aylin C., additional

Published
2022
Full Text
View/download PDF

4. Ocular Hypotensive Activity of Prostaglandin F2α (PGF2α) Analogs with Neutral Substituents at Position 1 is Predicted by the Isolated Cat Iris Sphincter Smooth Muscle Preparation but not Ca+ Signalling in Swiss 3T3 Cells

Author

Burk, Robert M., Woodward, David F., Krauss, Achim H.-P., Chen, June, Protzmann, Charles E., Williams, Linda S., Chan, Ming F., Honn, Kenneth V., editor, Marnett, Lawrence J., editor, Nigam, Santosh, editor, Dennis, Edward, editor, and Serhan, Charles, editor

Published
2002
Full Text
View/download PDF

9. Contributors

Author

Alexander, Stephen P.H., primary, Balvers, Michiel, additional, Bradshaw, Heather B., additional, De Petrocellis, Luciano, additional, Di Marzo, Vincenzo, additional, Hansen, Harald S., additional, Hassing, Helle Adser, additional, Hermanson, Daniel J., additional, Kingsley, Philip J., additional, Kleberg, Karen, additional, Leishman, Emma, additional, Marnett, Lawrence J., additional, Meijerink, Jocelijn, additional, Piscitelli, Fabiana, additional, Plastina, Pierluigi, additional, Tsuboi, Kazuhito, additional, Ueda, Natsuo, additional, Uyama, Toru, additional, Wang, Jenny W., additional, Watanabe, Kikuko, additional, Witkamp, Renger, additional, and Woodward, David F., additional

Published
2015
Full Text
View/download PDF

11. Prostanoid receptors in GtoPdb v.2021.2

Author

Clapp, Lucie, primary, Giembycz, Mark, primary, Heinemann, Akos, primary, Jones, Robert L., primary, Narumiya, Shuh, primary, Norel, Xavier, primary, Sugimoto, Yukihiko, primary, Woodward, David F., primary, and Yao, Chengcan, primary

Published
2021
Full Text
View/download PDF

12. The ultra-long lasting intraocular pressure reduction of JV-GL1 is mediated by EP(2) receptors

Author

Bertrand, Jacques A, Woodward, David F, Sherwood, Joseph M, Wang, Jenny W, and Overby, Darryl R

Subjects
Mice, Inbred C57BL, Mice, Tonometry, Ocular, Animals, Ocular Hypertension, Ocular Hypotension, Ophthalmic Solutions, Article, Antihypertensive Agents, Intraocular Pressure
Abstract

BACKGROUND: A single application of JV-GL1 substantially lowers non-human primate intraocular pressure (IOP) for about a week, independent of dose. This highly protracted effect does not correlate with its ocular bio-disposition, or correlate with the once-daily dosing regimen for other prostanoid EP(2) receptor such as trapenepag or omidenepag. The underlying pharmacological mechanism for the multi-day extended activity of JV-GL1 is highly intriguing. The present studies were intended to determine EP(2) receptor involvement in mediating the long-term ocular hypotensive activity of JV-GL1 by using mice genetically deficient in EP(2) receptors. METHODS: The protracted intraocular pressure reduction produced by JV-GL1 was investigated in C57BL/6J and EP(2) receptor knock-out mice (B6.129-Ptger2(tm1Brey)/J; EP(2)KO). Both ocular normotensive and steroid induced ocular hypertensive (SI-OHT) mice were studied. Intraocular pressure (IOP) was measured tonometrically under general anesthesia. Aqueous humor outflow facility was measured ex vivo using iPerfusion in normotensive C57BL/6J mouse eyes perfused with 100 nM de-esterified JV-GL1 and in SI-OHT C57BL/6J mouse eyes that had received topical JV-GL1 (0.01%) 3 days previously. RESULTS: Both the initial one day and protracted multi-day effects of JV-GL1 in the steroid induced ocular hypertension model for glaucoma, were abolished by deletion of the gene encoding the EP(2) receptor. Thus, JV-GL1 did not lower IOP in SI-OHT EP(2)KO mice, but in littermate SI-OHT EP(2)WT control mice JV-GL1 statistically significantly lowered IOP for 4–6 days. CONCLUSIONS: Both the one-day and long-term effect of JV-GL1 on IOP are entirely EP(2) receptor dependent.

Published
2020

13. Deletion of the gene encoding prostamide/prostaglandin F synthase reveals an important role in regulating intraocular pressure

Author

Bertrand, Jacques A, primary, Woodward, David F, additional, Sherwood, Joseph M, additional, Spenlehauer, Alice, additional, Silvestri, Cristoforo, additional, Piscitelli, Fabiana, additional, Marzo, Vincenzo Di, additional, Yamazaki, Maya, additional, Sakimura, Kenji, additional, Inoue, Yoko, additional, Watanabe, Kikuko, additional, and Overby, Darryl R, additional

Published
2021
Full Text
View/download PDF

14. Levels of bimatoprost acid in the aqueous humour after bimatoprost treatment of patients with cataract

Author

Cantor, Louis B., Hoop, Joni, Wudunn, Darrell, Yung, Chi-Wah, Catoira, Yara, Valluri, Shailaja, Cortes, Arnold, Acheampong, Andrew, Woodward, David F., and Wheeler, Larry A.

Subjects
Drug therapy -- Patient outcomes, Drug therapy -- Research, Cataract -- Care and treatment, Bimatoprost -- Dosage and administration, Aqueous humor -- Analysis, Hydrolysis -- Analysis, Health
Published
2007

15. Prostaglandin F(sub 2aplha) formation from prostaglandin H2 by prostaglandin F synthase (PGFS): Crystal structure of PGFS containing bimatoprost

Author

Komoto, Junichi, Yamada, Taro, Watanabe, Kikuko, Woodward, David F., and Takusagawa, Fusao

Subjects
Synthetic prostaglandins F -- Chemical properties, Synthetic prostaglandins F -- Structure, Crystals -- Structure, Crystals -- Research, Biological sciences, Chemistry
Abstract

The catalytic mechanism of prostaglandin H2 (PGH2) 9,11-endoperoxide reductase is examined by determining the crystal structure of prostaglandin F synthase (PGFS)[ NADPH + BMP (bimatoprost)]. The formation of PGH(sub 2alpha) from PGH2 involves a direct transfer from the bound NADPH to the endoperoxide of PGH2 without the participation of specific amino acid residues.

Published
2006

17. The inflow and outflow of anti-glaucoma drugs

Author

Woodward, David F. and Gil, Daniel W.

Subjects
Glaucoma -- Drug therapy, Pharmaceutical research, Biological sciences, Chemistry, Pharmaceuticals and cosmetics industries
Abstract

The treatment of glaucoma by reducing intraocular pressure has relied traditionally on inhibiting aqueous humor secretion (inflow), However, recent therapeutic approaches have targeted aqueous humor outflow. Prostanoid FP receptor agonists selectively increase uveoscleral outflow and the prostamide analog bimatoprost alters trabecular and uveoscleral outflow. An emerging therapeutic strategy is direct neuroprotection of retinal ganglion cells, which are selectively lost in glaucoma.

Published
2004

22. Prostanoid receptors (version 2020.4) in the IUPHAR/BPS Guide to Pharmacology Database

Author

Breyer, Richard M., primary, Clapp, Lucie, primary, Coleman, Robert A., primary, Giembycz, Mark, primary, Heinemann, Akos, primary, Hills, Rebecca, primary, Jones, Robert L., primary, Narumiya, Shuh, primary, Norel, Xavier, primary, Pettipher, Roy, primary, Sugimoto, Yukihiko, primary, Uddin, Mohib, primary, Woodward, David F., primary, and Yao, Chengcan, primary

Published
2020
Full Text
View/download PDF

24. Gene deletion studies reveal a critical role for prostamide/prostaglandin F2αsynthase in prostamide F2αformation

Author

Bertrand, Jacques A, primary, Woodward, David F, additional, Sherwood, Joseph M, additional, Spenlehauer, Alice, additional, Silvestri, Cristoforo, additional, Piscitelli, Fabiana, additional, Di Marzo, Vincenzo, additional, Yamazaki, Maya, additional, Sakimura, Kenji, additional, Watanabe, Kikuko, additional, and Overby, Darryl R, additional

Published
2020
Full Text
View/download PDF

26. Prostanoid receptors (version 2019.5) in the IUPHAR/BPS Guide to Pharmacology Database

Author

Breyer, Richard M., primary, Clapp, Lucie, primary, Coleman, Robert A., primary, Giembycz, Mark, primary, Heinemann, Akos, primary, Hills, Rebecca, primary, Jones, Robert L., primary, Narumiya, Shuh, primary, Norel, Xavier, primary, Pettipher, Roy, primary, Sugimoto, Yukihiko, primary, Uddin, Mohib, primary, Woodward, David F., primary, and Yao, Chengcan, primary

Published
2019
Full Text
View/download PDF

29. The role of EP2 receptors in mediating the ultra-long-lasting intraocular pressure reduction by JV-GL1.

Author

Bertrand, Jacques A., Woodward, David F., Sherwood, Joseph M., Wang, Jenny W., and Overby, Darryl R.

Abstract

Background A single application of JV-GL1 substantially lowers non-human primate intraocular pressure (IOP) for about a week, independent of dose. This highly protracted effect does not correlate with its ocular biodisposition or correlate with the once-daily dosing regimen for other prostanoid EP2 receptor agonists such as trapenepag or omidenepag. The underlying pharmacological mechanism for the multiday extended activity of JV-GL1 is highly intriguing. The present studies were intended to determine EP2 receptor involvement in mediating the long-term ocular hypotensive activity of JV-GL1 by using mice genetically deficient in EP2 receptors. Methods The protracted IOP reduction produced by JV-GL1 was investigated in C57BL/6J and EP2 receptor knock-out mice (B6.129-Ptger2tm1Brey/J; EP2KO). Both ocular normotensive and steroid-induced ocular hypertensive (SI-OHT) mice were studied. IOP was measured tonometrically under general anaesthesia. Aqueous humour outflow facility was measured ex vivo using iPerfusion in normotensive C57BL/6J mouse eyes perfused with 100 nM de-esterified JV-GL1 and in SI-OHT C57BL/6J mouse eyes that had received topical JV-GL1 (0.01%) 3 days prior. Results Both the initial 1-day and the protracted multiday effects of JV-GL1 in the SI-OHT model for glaucoma were abolished by deletion of the gene encoding the EP2 receptor. Thus, JV-GL1 did not lower IOP in SI-OHT EP2KO mice, but in littermate SI-OHT EP2WT control mice, JV-GL1 statistically significantly lowered IOP for 4-6 days. Conclusions Both the 1-day and the long-term effects of JV-GL1 on IOP are entirely EP2 receptor dependent. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

33. Cloning of human prostanoid receptors

Author

Pierce, Kristen L., Gil, Daniel W., Woodward, David F., and Regan, John W.

Subjects
Prostanoids -- Research, Cloning -- Research, Biological sciences, Chemistry, Pharmaceuticals and cosmetics industries
Abstract

The cloning of prostanoid receptors of prostaglandins and thromboxanes have been recorded raising important issues on the diversity, distribution and physiological roles of these receptors. The use of homology based screening may result in the discovery of additional putative subtypes. The cloning of prostanoid receptor genes is expected to benefit genetic manipulations in the future.

Published
1995

41. Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere.

Author

Woodward, David F., Wang, Jenny W., Stamer, W. Daniel, Lütjen-Drecoll, E., Krauss, Achim H.-P., and Toris, Carol B.

Abstract

For >2 decades, EP2 agonists have been the subject of antiglaucoma research and development by scientists in industry and academia around the world. The road has led to the recent approval of the first drug of this class. This article reviews the development of EP2 agonists from conception to clinical approval, discussing pharmacology, structure, biodistribution, therapeutics, and drug delivery. An extensive list of source references is provided for the reader's benefit. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

42. FAAH-Catalyzed C–C Bond Cleavage of a New Multitarget Analgesic Drug

Author

Ligresti, Alessia, primary, Silvestri, Cristoforo, additional, Vitale, Rosa Maria, additional, Martos, Jose L., additional, Piscitelli, Fabiana, additional, Wang, Jenny W., additional, Allarà, Marco, additional, Carling, Robert W., additional, Luongo, Livio, additional, Guida, Francesca, additional, Illiano, Anna, additional, Amoresano, Angela, additional, Maione, Sabatino, additional, Amodeo, Pietro, additional, Woodward, David F., additional, Di Marzo, Vincenzo, additional, and Marino, Gennaro, additional

Published
2018
Full Text
View/download PDF

43. The role of EP2receptors in mediating the ultra-long-lasting intraocular pressure reduction by JV-GL1

Author

Bertrand, Jacques A, Woodward, David F, Sherwood, Joseph M, Wang, Jenny W, and Overby, Darryl R

Abstract

BackgroundA single application of JV-GL1 substantially lowers non-human primate intraocular pressure (IOP) for about a week, independent of dose. This highly protracted effect does not correlate with its ocular biodisposition or correlate with the once-daily dosing regimen for other prostanoid EP2receptor agonists such as trapenepag or omidenepag. The underlying pharmacological mechanism for the multiday extended activity of JV-GL1 is highly intriguing. The present studies were intended to determine EP2receptor involvement in mediating the long-term ocular hypotensive activity of JV-GL1 by using mice genetically deficient in EP2receptors.MethodsThe protracted IOP reduction produced by JV-GL1 was investigated in C57BL/6J and EP2receptor knock-out mice (B6.129-Ptger2tm1Brey/J; EP2KO). Both ocular normotensive and steroid-induced ocular hypertensive (SI-OHT) mice were studied. IOP was measured tonometrically under general anaesthesia. Aqueous humour outflow facility was measured ex vivo using iPerfusionin normotensive C57BL/6J mouse eyes perfused with 100 nM de-esterified JV-GL1 and in SI-OHT C57BL/6J mouse eyes that had received topical JV-GL1 (0.01%) 3 days prior.ResultsBoth the initial 1-day and the protracted multiday effects of JV-GL1 in the SI-OHT model for glaucoma were abolished by deletion of the gene encoding the EP2receptor. Thus, JV-GL1 did not lower IOP in SI-OHT EP2KO mice, but in littermate SI-OHT EP2WT control mice, JV-GL1 statistically significantly lowered IOP for 4–6 days.ConclusionsBoth the 1-day and the long-term effects of JV-GL1 on IOP are entirely EP2receptor dependent.

Published
2021
Full Text
View/download PDF

47. FAAH-Catalyzed C–C Bond Cleavage of a New Multitarget Analgesic Drug.

Author

Ligresti, Alessia, Silvestri, Cristoforo, Vitale, Rosa Maria, Martos, Jose L., Piscitelli, Fabiana, Wang, Jenny W., Allarà, Marco, Carling, Robert W., Luongo, Livio, Guida, Francesca, Illiano, Anna, Amoresano, Angela, Maione, Sabatino, Amodeo, Pietro, Woodward, David F., Di Marzo, Vincenzo, and Marino, Gennaro

Published
2019
Full Text
View/download PDF

49. Method for trating pain

Author

ROSSI, Francesco, DI MARZO VINCENZO, DE PETROCELLIS LUCIANO, MAIONE, Sabatino, DE NOVELLIS, Vito, WOODWARD DAVID F., Rossi, Francesco, DI MARZO, Vincenzo, DE PETROCELLIS, Luciano, Maione, Sabatino, DE NOVELLIS, Vito, and WOODWARD DAVID, F.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results